Core Viewpoint - Neuralink is set to begin mass production of brain-machine interface devices in 2026, transitioning to a streamlined and nearly fully automated surgical process [1][19]. Group 1: Company Overview - Neuralink was founded in 2016 with the goal of enabling direct control of computers through neural signals via a coin-sized brain chip [4]. - The company focuses on treating neurological disorders such as paralysis, muscular atrophy, Parkinson's disease, Alzheimer's, and vision impairments [4]. - As of September 2025, Neuralink had served only 12 patients, which raises questions about the pace of its clinical applications despite significant market demand [2][18]. Group 2: Technological Advancements - The upcoming surgical procedure will simplify the implantation of brain chips by allowing electrode wires to penetrate the dura mater without the need for surgical removal, reducing complexity and risk [2][20]. - This new "minimally invasive" approach is expected to lower costs, risks, and recovery times, making the procedure more standardized and accessible [2][20]. Group 3: Clinical Trials and Milestones - The first human trial participant, Noland Arbaugh, was implanted with a Neuralink device in January 2024, enabling him to post on social media and play video games using only his thoughts [4][16]. - By December 2025, the number of participants in clinical trials had increased to 20, indicating a gradual acceleration in the pace of trials [18]. Group 4: Future Implications - Elon Musk envisions Neuralink not only as a medical device but also as a means for humanity to keep pace with potential advanced artificial intelligence, suggesting that brain-machine interfaces could enhance human capabilities [6][7]. - The potential for widespread adoption of brain-machine interfaces could lead to significant advancements in human progress, allowing for skills to be updated like software [7].

Core Insights - The newly established company Gestala, co-founded by former CEO of Brain Tiger Technology Peng Lei and Chen Tianqiao, aims to explore next-generation brain signal reading and analysis through ultrasound brain-machine interface technology [2][5]. Company Overview - Gestala has set up operations in Chengdu Tianfu International Bio-City and is located in the Shanghai Brain-Machine Interface Industrial Cluster [2][5]. - The company plans to develop its products in phases, with the first generation focusing on chronic pain management and expected to initiate registration processes with the National Medical Products Administration (NMPA) by the end of 2026 [2][5]. Technology and Innovation - The ultrasound technology used by Gestala can indirectly decode neural activity by capturing blood flow signals, covering 25% of the entire brain volume while reaching deep brain areas and enabling simultaneous monitoring of multiple brain regions [2][5]. - This technology addresses the long-standing challenge in brain science research of balancing whole-brain imaging and real-time response, which has been difficult with existing methods like fMRI and invasive electrodes [2][5]. Industry Context - Chen Tianqiao has invested $1 billion over the past decade to support global brain science research and has successfully incubated multiple brain-machine interface companies through his firm, Shengda [3][6]. - The ultrasound brain-machine interface sector has seen significant financing activity, with companies like Merge Labs planning to raise $250 million at an $850 million valuation, and Nudge securing $100 million in Series A funding [3][6].

2026年二级市场的第一个热门概念属于脑机接口。 板块3日涨幅17.98% 新年伊始，脑机接口概念股集体沸腾，2026年以来的3个交易日里，人脑工程板块累计涨幅达到17.98%。 消息面上，马斯克近日表示，其脑机接口公司Neuralink将于2026年开始对脑机接口设备进行大规模生产，并转向更加精简和几乎完全自动化的外科手术流 程。此外，据报道，脑机接口"独角兽"强脑科技近期完成约20亿元融资，为脑机接口领域除Neuralink以外世界第二大规模融资，进一步点燃投资者热情。 在上述消息影响下，1月5日—6日，人脑工程板块掀起涨停潮，多只个股连续两个交易日"20cm"涨停。1月7日，美好医疗再度"20cm"涨停，南京熊猫、岩山 科技等个股斩获三连板。爱朋医疗、麦澜德、伟思医疗等个股则出现回调，其中爱朋医疗跌逾11%。 自1月5日起，A股人脑工程板块"起飞"，1月5日—6日，板块内个股掀起涨停潮。1月7日，尽管板块内部分个股出现回调，但板块3日涨幅仍接近18%，创新 医疗、南京熊猫等多只概念股斩获三连板。 股价狂飙背后，脑机接口，这一曾只存在于科幻作品中的概念，正在加速走进现实。在业内专家看来，2026年有望成为 ...

Core Viewpoint - Aihui Long (688575.SH) announced a strategic cooperation with Shenzhen Brain Machine Starlink Technology Co., Ltd. to explore brain-computer interface technology, which has raised regulatory concerns due to the sudden nature of the announcement and the company's recent poor performance in its core business [2][3][5]. Group 1: Company Announcement and Market Reaction - Aihui Long signed a strategic cooperation framework agreement with Brain Machine Starlink on January 6, focusing on brain-computer interface technology development and commercialization [2]. - Following the announcement, Aihui Long's stock price surged from 14.64 CNY to 15.80 CNY, marking a 6.52% increase with a trading volume up by 299% compared to the previous day [2]. - The Shanghai Stock Exchange issued an inquiry to Aihui Long regarding the feasibility of the cooperation, including questions about the partnership's rationale and potential insider trading [2][5]. Group 2: Financial Performance and Concerns - Aihui Long's financial performance has been declining, with a 7.69% drop in revenue and a 72.36% decrease in net profit for the first three quarters of 2025 [3][6]. - The company is attempting to pivot into the growing brain-computer interface market amid stagnation in its core business of in vitro diagnostic instruments [3]. - The inquiry from the exchange also focused on the reasons behind the significant decline in Aihui Long's financials and the potential impact of the new cooperation on its existing business [6]. Group 3: Details on the Cooperation Partner - Brain Machine Starlink was established only four months prior to the announcement, with a registered capital of 5 million CNY and a focus on comprehensive diagnosis, treatment, and rehabilitation of brain diseases [3][4]. - Both companies share the same registered address in Shenzhen, raising questions about the legitimacy and depth of the partnership [4]. - The products under development by Brain Machine Starlink, including non-invasive brain-computer interface devices, are still in early stages and have not yet entered the registration phase [4].

Market Overview - The Shanghai Composite Index (沪指) achieved a record 13 consecutive days of gains, closing near 4100 points, with a 1.5% increase on January 6, 2026. Over 4100 stocks rose, and the total trading volume in the Shanghai and Shenzhen markets reached 2.81 trillion yuan [2][7] - Goldman Sachs forecasts a 15% to 20% annual increase in the Chinese stock market for 2026 and 2027, recommending an overweight position in A-shares and H-shares [2][7] Commodities - Citigroup raised its short-term copper price target to $14,000 per ton but warned that the price increase may be nearing its end, with January potentially being the peak for 2026. Prices above $13,000 could stimulate increased scrap copper recovery [3][8] - China is initiating a new round of mineral exploration, with expectations that the demand from emerging sectors like AI will drive the commodity cycle, supporting a bullish outlook for non-ferrous metals [3][8] Technology and Innovation - The brain-computer interface sector is experiencing rapid growth, with several companies announcing significant funding and production plans. Strong Brain Technology secured approximately 2 billion yuan in financing, and Elon Musk's company is set to mass-produce brain-computer interface devices [3][8] - The humanoid robot industry is projected to reach production levels of 100,000 to 200,000 units by 2026, entering a phase of scale and commercialization driven by cost reductions and technological advancements [9][10] Monetary Policy - The People's Bank of China (央行) indicated a flexible approach to monetary policy for 2026, with potential interest rate cuts and reserve requirement ratio reductions aimed at promoting high-quality economic development and price recovery [9]

分析师及联系人 [Table_Author] 行业研究丨点评报告丨软件与服务 [Table_Title] Neuralink 将开启大规模量产，脑机接口产业商 业化落地有望加速 报告要点 [Table_Summary] 北京时间 1 月 1 日上午，埃隆・马斯克在社交媒体 X 上表示，其脑机接口公司 Neuralink 今年 将开始实现"大规模生产"脑机接口设备，并转向更精简、几乎完全自动化的外科手术流程。 当前时点，以 Neuralink 为代表的脑机接口产业正通过技术突破推动其商业化进展。在其规模 化量产预期和技术突破的催化下，脑机接口产业商业化落地有望加速，惠及全产业链。建议关 注三条主线：1、侵入式脑机接口海外先进产业链的国内映射标的；2、非侵入式脑机接口在消 费场景的产品落地相关标的；3、脑机接口下游应用端相关标的。 宗建树 陈耀文 SAC：S0490520030004 SAC：S0490525070002 SFC：BUX668 丨证券研究报告丨 请阅读最后评级说明和重要声明 %% %% %% %% research.95579.com 1 软件与服务 cjzqdt11111 [Table_Titl ...

Core Insights - The article highlights the significant stock price increase of Sanbo Neurosurgery, driven by developments in the brain-computer interface (BCI) sector, particularly following Elon Musk's announcement regarding Neuralink's plans for mass production of BCI devices by 2026 [1][3][4]. Company Performance - Sanbo Neurosurgery's stock price rose to 93.82 yuan per share, marking a 10.45% increase on January 7, 2026, with a cumulative increase of 59.07% since the beginning of the year [1][3]. - The stock reached a peak of 100 yuan per share during trading, reflecting a 17.72% intraday increase [3]. Major Shareholder Insights - TBP3Doctors (HK) Limited, the largest shareholder of Sanbo Neurosurgery, acquired approximately 30.465 million shares at 4.44 yuan per share in December 2015, totaling an investment of 135 million yuan [1][6]. - TBP has since recouped its initial investment through partial share sales, with a current holding valued at approximately 2.834 billion yuan, resulting in a total profit of about 2.885 billion yuan, yielding a return of over 21 times [1][6][7]. Investment Background - TBP is controlled by Li Shujun, founder of Zhi Xin Capital, which manages over 8 billion USD and has invested in notable companies such as Douban and Haier [2][7]. - Li Shujun has a history of successful investments, preferring to acquire significant equity stakes in early-stage companies and later exiting through public offerings [8][9]. Industry Developments - The BCI sector is gaining traction, with Sanbo Neurosurgery being recognized as a leading player due to its strong capabilities in neurosurgery [3][4]. - Recent advancements include the successful completion of the world's first invasive BCI trial in China, which restored motor function in a paralyzed patient [4]. Strategic Investments - Sanbo Neurosurgery is actively investing in the BCI space, committing 87 million yuan to acquire a 29% stake in a venture capital fund focused on brain science tools and early-stage companies in neurological and psychiatric disorders [5]. - Additional investments include 10 million yuan for an 11.11% stake in another fund targeting medical devices for brain disease diagnosis and treatment [5].

Group 1 - Neuralink plans to start mass production of brain-machine interface devices in 2026 with a nearly fully automated surgical process [1] - The announcement led to a surge in A-share brain-machine interface stocks from January 5 to January 6, followed by a pullback on January 7 [1] - Nanjing Panda stated that it has no mature products related to brain-machine interfaces and that the concept will not materially impact its current operations [1] Group 2 - Plittech announced that its LCP film products, suitable for flexible electrode materials in brain-machine interfaces, are seeing positive market prospects as the industry matures [2] - Plittech is the only domestic company capable of large-scale production of LCP film technology and is currently conducting clinical trials with overseas clients [2] - Yachuang Electronics mentioned its subsidiary's membership in the brain-machine interface industry alliance and its application of AFE96× chips in EEG and EMG detection [2] Group 3 - Hansan Technology is monitoring developments in the brain-machine interface field and may enter the market in the future, although it currently focuses on smart audio applications [3]

格隆汇1月7日丨领益智造(002600.SZ)在投资者互动平台表示，公司与国内首家脑机接口领域独角兽企 业浙江强脑科技有限公司达成战略合作伙伴关系。 ...

每经AI快讯，1月7日，Wind数据显示，A股市场共计98只个股涨停。机器人板块锋龙股份9连板；商业 航天板块雷科防务6连板、城建发展4连板；脑机接口板块多股连板，创新医疗、岩山科技等3连板。 每经AI快讯，1月7日，Wind数据显示，A股市场共计98只个股涨停。机器人板块锋龙股份9连板；商业 航天板块雷科防务6连板、城建发展4连板；脑机接口板块多股连板，创新医疗、岩山科技等3连板。 ...